Our finding that the level of EZH2 can be downregulated by the chemotherapeutic agent CPT suggests that co-treatment of PCa with CPT may increase the sensitivity of CRPC cells to the EZH2 inhibitor. This evidence concerns the gene EZH2 and posterior cortical atrophy.